Robilas (Bilastine)

Robilas is a well-known non-sedating antihistamine used for the treatment of allergic rhinoconjunctivitis and urticaria. The active ingredient, Bilastine, was originally developed in Spain by the pharmaceutical research company Faes Farma. It is a second-generation H1 receptor antagonist designed to provide relief from allergy symptoms without the typical drowsiness associated with earlier medications.

While Faes Farma holds the original patent and is the primary manufacturer in Spain, the brand is distributed globally through various licensing agreements. In Italy, it is widely marketed and distributed by the Menarini Group (A. Menarini Industrie Farmaceutiche Riunite S.r.l.), one of the largest Italian pharmaceutical companies. The manufacturing often takes place across various European facilities to serve local markets, adhering to strict EU pharmaceutical standards.

The brand remains under the ultimate ownership of Faes Farma, which continues to manage the production and licensing rights globally. The partnership with the Menarini Group ensures its availability across numerous international territories, where it is often sold under different brand names depending on the specific region.